US regulators want to see more efficacy data before they consider approving Sanofi and Regeneron’s Dupixent in a skin condition characterized by chronic hives, Sanofi announced Friday.
The anti-inflammatory megablockbuster was handed a rejection in chronic spontaneous urticaria (CSU), a condition with a patient population that executives have said is…
Click here to view original post
